Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2021 | $37.00 | Buy | Roth Capital |
10-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
SCHEDULE 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00
MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time. Benzinga All-Access Show Date: Tuesday, April 15, 2025Time: 10:50 a.m. Eastern TimeLive Webcast: https://youtube.com/live/YVur35nB9nc?feature=share The interview will also be archived on the Investors section of the Company's website. About BioRestorative Therapies
MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative's lead clinical candidate. The safety and efficacy of BRTX-100 in treating chronic lumbar disc disease ("cLDD") is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. The U.S. Food and Drug A
MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. "2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement," said Lance Alstodt, BioRestorative's Chief Executive Officer. "Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progr
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. "2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement," said Lance Alstodt, BioRestorative's Chief Executive Officer. "Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progr
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its 2024 financial results after market close on Thursday, March 27, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. 2024 Results Conference Call Details: Date:Thursday, March 27, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:726526 The call will also be broadcast live and arch
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain – – Company to host webcasted conference call today at 10:30am EST – MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application f